title: ÐÑÐ¾ÑÐµÐ¾Ð¼Ð½ÑÐ¹ Ð°Ð½Ð°Ð»Ð¸Ð· Ð³Ð°Ð¿ÑÐ¾Ð³Ð»Ð¾Ð±Ð¸Ð½Ð° Ð¸ Ð¾ÑÐµÐ½ÐºÐ° ÐµÐ³Ð¾ ÑÐ¾Ð»Ð¸ ÐºÐ°Ðº Ð¿Ð¾ÑÐµÐ½ÑÐ¸Ð°Ð»ÑÐ½Ð¾Ð³Ð¾ Ð¾Ð½ÐºÐ¾Ð¼Ð°ÑÐºÐµÑÐ° Ð³Ð»Ð¸Ð¾Ð±Ð»Ð°ÑÑÐ¾Ð¼Ñ
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: Proteomic analysis of Haptoglobin and its role as Glioblastoma biomarker
Creators: name: ÐÐ°Ð±Ð°ÑÐµÐ½ÐºÐ¾, Ð¤ÐµÐ´Ð¾Ñ
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2021
Subjects: Ð³Ð°Ð¿ÑÐ¾Ð³Ð»Ð¾Ð±Ð¸Ð½
Ð³Ð»Ð¸Ð¾Ð±Ð»Ð°ÑÑÐ¾Ð¼Ð°
Ð±Ð¸Ð¾Ð¼Ð°ÑÐºÐµÑ
ÑÐ»ÐµÐºÑÑÐ¾ÑÐ¾ÑÐµÐ·
Ð²ÐµÑÑÐµÑÐ½ Ð±Ð»Ð¾ÑÑÐ¸Ð½Ð³
Ð¿ÑÐ¾ÑÐµÐ¾Ð¼Ð½ÑÐ¹ Ð°Ð½Ð°Ð»Ð¸Ð·
haptoglobin
glioblastoma
biomarker
electrophoresis
western blot
proteomic analysis

description: ÐÐ°Ð¿ÑÐ¾Ð³Ð»Ð¾Ð±Ð¸Ð½ (Hp) â Î±2-Ð³Ð»Ð¸ÐºÐ¾Ð¿ÑÐ¾ÑÐµÐ¸Ð½, Ð±ÐµÐ»Ð¾Ðº Ð¾ÑÑÑÐ¾Ð¹ ÑÐ°Ð·Ñ, Ð³Ð»Ð°Ð²Ð½Ð¾Ð¹ Ð±Ð¸Ð¾Ð»Ð¾Ð³Ð¸ÑÐµÑÐºÐ¾Ð¹ ÑÑÐ½ÐºÑÐ¸ÐµÐ¹ ÐºÐ¾ÑÐ¾ÑÐ¾Ð³Ð¾ ÑÐ²Ð»ÑÐµÑÑÑ ÑÐ²ÑÐ·ÑÐ²Ð°Ð½Ð¸Ðµ Ñ Ð²ÑÑÐ¾ÐºÐ¾Ð¹ Ð°ÑÑÐ¸Ð½Ð½Ð¾ÑÑÑÑ ÑÐ²Ð¾Ð±Ð¾Ð´Ð½Ð¾Ð³Ð¾ Ð³ÐµÐ¼Ð¾Ð³Ð»Ð¾Ð±Ð¸Ð½Ð°, Ð¿ÑÐµÐ´Ð¾ÑÐ²ÑÐ°ÑÐ°Ñ ÐµÐ³Ð¾ Ð¾ÐºÐ¸ÑÐ»Ð¸ÑÐµÐ»ÑÐ½ÑÑ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÑ. ÐÐ¾Ð½ÑÐµÐ½ÑÑÐ°ÑÐ¸Ñ Hp Ð¸Ð·Ð¼ÐµÐ½ÑÐµÑÑÑ Ð¿ÑÐ¸ Ð¿Ð°ÑÐ¾Ð»Ð¾Ð³Ð¸Ð¸, Ð²Ð²Ð¸Ð´Ñ ÑÐµÐ³Ð¾ Ð¾Ð½ Ð½Ð°ÑÐ¾Ð´Ð¸Ñ ÑÐ²Ð¾Ðµ Ð¿ÑÐ¸Ð¼ÐµÐ½ÐµÐ½Ð¸Ðµ Ð¸ Ð² ÐºÐ»Ð¸Ð½Ð¸ÑÐµÑÐºÐ¾Ð¹ Ð¿ÑÐ°ÐºÑÐ¸ÐºÐµ. Ð Ð¾ÑÐ³Ð°Ð½Ð¸Ð·Ð¼Ðµ ÑÐµÐ»Ð¾Ð²ÐµÐºÐ° Ð¼Ð¾Ð¶Ð½Ð¾ Ð²ÑÑÑÐµÑÐ¸ÑÑ ÑÑÐ¸ Ð¼Ð°Ð¶Ð¾ÑÐ½ÑÑ ÑÐµÐ½Ð¾ÑÐ¸Ð¿Ð° Ð´Ð°Ð½Ð½Ð¾Ð³Ð¾ Ð±ÐµÐ»ÐºÐ° â Ð³Ð¾Ð¼Ð¾Ð·Ð¸Ð³Ð¾ÑÐ½ÑÐµ ÐÑ1-1 Ð¸ ÐÑ2-2 Ð¸ Ð³ÐµÑÐµÑÐ¾Ð·Ð¸Ð³Ð¾ÑÐ½ÑÐ¹ ÐÑ2-1, ÐºÐ¾ÑÐ¾ÑÑÐµ Ð¾Ð¿ÑÐµÐ´ÐµÐ»ÑÑÑÑÑ ÐºÐ¾Ð¼Ð±Ð¸Ð½Ð°ÑÐ¸ÐµÐ¹ Ð½Ð°ÑÐ»ÐµÐ´ÑÐµÐ¼ÑÑ Ð°Ð»Ð»ÐµÐ»ÑÐ½ÑÑ Ð²Ð°ÑÐ¸Ð°Ð½ÑÐ¾Ð². ÐÑÐ¾Ð¼Ðµ ÑÐ¾Ð³Ð¾, Hp Ð¿Ð¾Ð´Ð²ÐµÑÐ³Ð°ÐµÑÑÑ ÑÐ°Ð·Ð»Ð¸ÑÐ½ÑÐ¼ Ð¿Ð¾ÑÑÑÑÐ°Ð½ÑÐ»ÑÑÐ¸Ð¾Ð½Ð½ÑÐ¼ Ð¼Ð¾Ð´Ð¸ÑÐ¸ÐºÐ°ÑÐ¸ÑÐ¼ (ÐÐ¢Ð). ÐÐ»Ð¸Ð¾Ð±Ð»Ð°ÑÑÐ¾Ð¼Ð° (GBM) â Ð¾Ð´Ð½Ð° Ð¸Ð· Ð½Ð°Ð¸Ð±Ð¾Ð»ÐµÐµ Ð·Ð»Ð¾ÐºÐ°ÑÐµÑÑÐ²ÐµÐ½Ð½ÑÑ Ð¾Ð¿ÑÑÐ¾Ð»ÐµÐ¹ Ð³Ð¾Ð»Ð¾Ð²Ð½Ð¾Ð³Ð¾ Ð¼Ð¾Ð·Ð³Ð°. ÐÐµÑÐ¾Ð´Ñ ÑÐ°Ð½Ð½ÐµÐ¹ Ð´Ð¸Ð°Ð³Ð½Ð¾ÑÑÐ¸ÐºÐ¸ ÑÑÐ°Ð½Ð¾Ð²ÑÑÑÑ Ð°ÐºÑÑÐ°Ð»ÑÐ½ÑÐ¼ Ð¿Ð¾Ð´ÑÐ¾Ð´Ð¾Ð¼ Ð´Ð»Ñ ÑÐ²ÐµÐ»Ð¸ÑÐµÐ½Ð¸Ñ Ð¿ÑÐ¾Ð´Ð¾Ð»Ð¶Ð¸ÑÐµÐ»ÑÐ½Ð¾ÑÑÐ¸ Ð¶Ð¸Ð·Ð½Ð¸ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ Ð¿Ð¾Ð´Ð¾Ð±Ð½ÑÐ¼ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸ÐµÐ¼. ÐÐ¸Ð¾Ð¼Ð°ÑÐºÐµÑÑ Ð¼Ð¾Ð³ÑÑ Ð¿Ð¾Ð¼Ð¾ÑÑ Ð¿ÑÐ¸ ÑÐ°Ð½Ð½ÐµÐ¹ Ð´Ð¸Ð°Ð³Ð½Ð¾ÑÑÐ¸ÐºÐµ, Ð¸ Ð½ÐµÑÐºÐ¾Ð»ÑÐºÐ¾ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ð¹ ÑÐºÐ°Ð·ÑÐ²Ð°ÑÑ Ð½Ð° ÑÐ¾, ÑÑÐ¾ Ð³Ð°Ð¿ÑÐ¾Ð³Ð»Ð¾Ð±Ð¸Ð½ Ð¼Ð¾Ð¶ÐµÑ Ð±ÑÑÑ Ð¿Ð¾ÑÐµÐ½ÑÐ¸Ð°Ð»ÑÐ½ÑÐ¼ Ð¾Ð½ÐºÐ¾Ð¼Ð°ÑÐºÐµÑÐ¾Ð¼ Ð³Ð»Ð¸Ð¾Ð±Ð»Ð°ÑÑÐ¾Ð¼Ñ. Ð Ð½Ð°ÑÐµÐ¼ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ð¸ Ð¼Ñ Ð¿ÑÐ¾Ð°Ð½Ð°Ð»Ð¸Ð·Ð¸ÑÐ¾Ð²Ð°Ð»Ð¸ ÑÐ¾ÑÑÐ¾ÑÐ½Ð¸Ðµ Ð¿ÑÐ¾ÑÐµÐ¾ÑÐ¾ÑÐ¼ Hp Ð² Ð¿Ð»Ð°Ð·Ð¼Ðµ ÐºÑÐ¾Ð²Ð¸ Ñ Ð¿Ð¾Ð¼Ð¾ÑÑÑ 1D- (SDS-PAGE) Ð¸ 2D-ÑÐ»ÐµÐºÑÑÐ¾ÑÐ¾ÑÐµÐ·Ð° (2DE) Ð² ÑÐ¾ÑÐµÑÐ°Ð½Ð¸Ð¸ Ñ Ð²ÐµÑÑÐµÑÐ½-Ð±Ð»Ð¾ÑÑÐ¸Ð½Ð³Ð¾Ð¼. ÐÑ Ð¾Ð±Ð½Ð°ÑÑÐ¶Ð¸Ð»Ð¸, ÑÑÐ¾ Ð¾Ð±ÑÐ¸Ðµ ÑÑÐ¾Ð²Ð½Ð¸ Ð¿ÑÐ¾ÑÐµÐ¾ÑÐ¾ÑÐ¼ Î±2- Ð¸ Î²-ÑÐµÐ¿ÐµÐ¹ ÑÐ²ÐµÐ»Ð¸ÑÐ¸Ð²Ð°ÑÑÑÑ Ð² Ð¿Ð»Ð°Ð·Ð¼Ðµ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ GBM. ÐÐ¾Ð»ÑÑÐµÐ½Ð½ÑÐµ Ð´Ð°Ð½Ð½ÑÐµ ÑÐºÐ°Ð·ÑÐ²Ð°ÑÑ Ð½Ð° Ð²Ð¾Ð·Ð¼Ð¾Ð¶Ð½Ð¾ÑÑÑ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½Ð¸Ñ Ð¿ÑÐ¾ÑÐµÐ¾ÑÐ¾ÑÐ¼ Ð³Ð°Ð¿ÑÐ¾Ð³Ð»Ð¾Ð±Ð¸Ð½Ð° ÐºÐ°Ðº Ð¿Ð¾ÑÐµÐ½ÑÐ¸Ð°Ð»ÑÐ½Ð¾Ð³Ð¾ Ð±Ð¸Ð¾Ð¼Ð°ÑÐºÐµÑÐ° Ð¿Ð»Ð°Ð·Ð¼Ñ ÐºÑÐ¾Ð²Ð¸, ÑÐ¿ÐµÑÐ¸ÑÐ¸ÑÐ½Ð¾Ð³Ð¾ Ð´Ð»Ñ GBM.
description: Haptoglobin (Hp) is an acute-phase Î±2-glycoprotein that binds avidly to free hemoglobin and prevents its oxidative activity. The concentration of Hp in blood plasma changes in pathology, and this fact is applied in daily clinical practice. Humans have three major phenotypes of haptoglobin - homozygous ÐÑ1-1 and ÐÑ2-2, and heterozygous ÐÑ2-1, determined by a combination of allelic variants that are inherited. In addition, Hp undergoes various post-translational modifications (PTMs). Glioblastoma multiforme (GBM) is one of the most malignant brain tumors. Early diagnosis methods are becoming an important approach to increase the life expectancy of patients with this disease. Biomarkers can help with early diagnosis, and several studies indicate that haptoglobin may be a potential biomarker for glioblastoma. In our study, we have analyzed the state of Hp proteoforms in blood plasma using 1D (SDS-PAGE) and 2D electrophoresis (2DE) with the following Western blotting. We found that the total levels of Î±2- and Î²-chain proteoforms are up-regulated in the plasma of patients with GBM. Variability of the Î±2-chain proteoforms was also detected. This data shows the possibility to use proteoforms of haptoglobin as a potential GBM-specific plasma biomarker.